Latest From Nexstim PLC
Neuromodulation firm Nexstim has received regulatory clearance for its SmartFocus TMS system for treating major depressive disorder (MDD) in Australia.
Neuromodulation firm Nexstim will launch its SmartFocus TMS system for treating major depressive disorder (MDD) in Canada after signing an exclusive agreement with distributor Canada Health Solutions CHS.
The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.
The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."
Diagnostic Imaging Equipment & Supplies
- MRI, NMR
- Monitoring Equipment & Devices
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Neurology, Nervous System
- Nexstim Ltd.
- Nexstim Oy
- Western Europe
- Parent & Subsidiaries
- Nexstim PLC
- Senior Management
Janne Huhtala, CEO
Mikko Karvinen, CFO
Gustaf Jarnefelt, VP, R&D
Henri Hannula, VP, Sales Europe
- Contact Info
Phone: (358) 9 2727 1710
Elimäenkatu 9 B
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.